Drug Profile
Research programme: radiolabelled proteins - Jubilant Life Sciences/Med Discovery
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator DRAXIMAGE; Med Discovery
- Class Antineoplastics; Proteins; Radiopharmaceutical diagnostics
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Canada
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Switzerland
- 16 Jul 2016 No recent reports of development identified for research development in Cancer(Diagnosis) in Canada